Main menu

NEW YORK, Aug. 7 – Gene Logic spinoff Metrigenix announced on Tuesday its first deal, saying it would work with Neuralstem to co-develop low-density oligonucleotide microarrays designed to study gene expression in the central nervous system.

Metrigenix will provide its Flow-thru Chip technology, while privately held Neuralstem, a developer of stem-cell technology for the human central nervous system, will contribute the content.